L2M – Targeting several intrinsic regeneration pathways in the context of neurodegenerative diseases

Treatments for neurodegenerative disorders represent an unmet medical need, affecting more than 50 million people worldwide. Through extensive research, we have identified two innovative therapeutic targets that have demonstrated promising effects in enhancing the regeneration and resilience capacities of neurons in animal models of Amyotrophic lateral sclerosis and Huntington’s disease. Our approach not only has the potential to increase life expectancy but also significantly improve the quality of life for patients and their families. What sets us apart is our unique strategy, which targets two distinct pathways, enhancing the likelihood of clinical success and offering new hope to those affected by these devastating diseases.

The mission of Lab2Market is to promote entrepreneurship in Canada by providing researchers with the opportunity to critically test and evaluate the market potential of their innovations. This is achieved through funding, exercises, workshops, and mentorship from industry experts, all centered around exploration. Being the pioneers in describing these mechanisms and targets, these discoveries have the potential to be patented and facilitate the transition from academia to entrepreneurial and clinical settings. Therefore, we believe that we align perfectly with the Lab2Market program, aiming to stimulate innovation, entrepreneurship, and scientific translation toward clinical trials in Canada.

Faculty Supervisor:

Alex Parker

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Pharmaceuticals; Biotechnology

University:

Université de Montréal

Program: